School of Chemical Engineering, Engineering Campus, Universiti Sains Malaysia, Nibong Tebal, Pulau Pinang 14300, Malaysia.
Centre for Chemical Synthesis & Polymer Technology, Institute of Science (IoS), Kompleks Inspirasi, Universiti Teknologi MARA, Shah Alam, Selangor Darul Ehsan 40450, Malaysia.
Enzyme Microb Technol. 2024 Oct;180:110483. doi: 10.1016/j.enzmictec.2024.110483. Epub 2024 Jul 17.
Biocatalysis has emerged as a strong tool for the synthesis of active pharmaceutical ingredients (APIs). In the early twentieth century, whole cell biocatalysis was used to develop the first industrial biocatalytic processes, and the precise work of enzymes was unknown. Biocatalysis has evolved over the years into an essential tool for modern, cost-effective, and sustainable pharmaceutical manufacturing. Meanwhile, advances in directed evolution enable the rapid production of process-stable enzymes with broad substrate scope and high selectivity. Large-scale synthetic pathways incorporating biocatalytic critical steps towards >130 APIs of authorized pharmaceuticals and drug prospects are compared in terms of steps, reaction conditions, and scale with the corresponding chemical procedures. This review is designed on the functional group developed during the reaction forming alcohol functional groups. Some important biocatalyst sources, techniques, and challenges are described. A few APIs and their utilization in pharmaceutical drugs are explained here in this review. Biocatalysis has provided shorter, more efficient, and more sustainable alternative pathways toward existing small molecule APIs. Furthermore, non-pharmaceutical applications of biocatalysts are also mentioned and discussed. Finally, this review includes the future outlook and challenges of biocatalysis. In conclusion, Further research and development of promising enzymes are required before they can be used in industry.
生物催化已成为合成活性药物成分 (API) 的有力工具。在 20 世纪早期,全细胞生物催化被用于开发第一个工业生物催化过程,而酶的精确作用尚不清楚。多年来,生物催化已发展成为现代、经济高效和可持续药物制造的重要工具。同时,定向进化的进步使具有广泛底物范围和高选择性的过程稳定酶的快速生产成为可能。将包含 >130 种已授权药物和药物前景的 API 的生物催化关键步骤的大规模合成途径与相应的化学程序进行了比较,比较了步骤、反应条件和规模。本综述是根据形成醇官能团的反应过程中开发的官能团设计的。描述了一些重要的生物催化剂来源、技术和挑战。本文还介绍并讨论了一些 API 及其在药物中的应用。生物催化为现有的小分子 API 提供了更短、更高效和更可持续的替代途径。此外,还提到并讨论了生物催化剂的非药物应用。最后,本综述包括生物催化的未来展望和挑战。总之,在将有前途的酶投入工业应用之前,还需要进一步的研究和开发。